Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 126 clinical trials
Featured trial
Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-7)

This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS

pembrolizumab
KRAS
  • 30 views
  • 04 May, 2022
  • 60 locations
Featured trial
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

lung cancer
advanced lung cancer
lung metastases
recurrent non-small cell lung cancer
metastatic non-small cell lung cancer
  • 32 views
  • 04 May, 2022
  • 150 locations
Featured trial
  • 62 views
  • 27 Apr, 2022
  • 135 locations
Featured trial
Metastatic Colorectal Cancer with wild-type KRAS tumors.

Metastatic Colorectal Cancer with wild-type KRAS tumors.

  • 266 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is

advanced solid tumor
malignant solid tumor
solid tumor
  • 536 views
  • 22 Nov, 2021
  • 62 locations
Featured trial
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation.

advanced solid tumor
malignant solid tumor
solid tumor
solid tumors
  • 178 views
  • 19 Feb, 2021
  • 4 locations
Therascreen® KRAS RGQ PCR Kit

for the KRAS G12C mutation for potential inclusion into the Amgen Phase III clinical trial (Protocol No 20190172) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit

  • 0 views
  • 14 May, 2022
  • 1 location
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.

  • 1 views
  • 06 Mar, 2022
  • 1 location
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combination

  • 4 views
  • 06 May, 2022
  • 1 location
Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients

after 4 months of mFOLFIRINOX chemotherapy as following: Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile and with KRAS mutation randomization between

  • 0 views
  • 27 Jan, 2021
  • 29 locations